KAAPA Biotech aims to set purity and quality standards for mushroom products with clinically validated health benefits.
Finland’s KAAPA Biotech has secured €9 million in new funding to advance its development of functional mushroom ingredients. Based in Karjalohja, Finland, the company specializes in researching, developing and sustainably producing mushroom products with clinically validated health benefits. The strategic investment will enable KAAPA to expand production, strengthen vertical integration and scale its operations to meet accelerating demand from the wellness, nutrition and supplement industries.
Functional mushrooms have long been recognized for their restorative and preventive properties, and their modern resurgence is being driven by growing evidence of their effects on cognitive health, immunity and longevity. Varieties such as lion’s mane, chaga, cordyceps and reishi contain bioactive compounds that can influence a wide range of biological processes, from energy metabolism and neuroprotection to stress resilience.
According to KAAPA, lion’s mane supports nerve growth and cognitive function through hericenones and hericenes, while chaga contains betulinic acid and inotodiol, which are recognized for their potent antioxidant activity, immune modulation and cellular protection. Cordyceps enhances endurance and energy production by increasing ATP synthesis, and reishi supports relaxation and immune balance through triterpenoids like lucidenic acids.
KAAPA CEO Eric Puro told us that chaga in particular has demonstrated significant potential as a longevity ingredient.
“Chaga has long been recognised for its extraordinary antioxidant profile, and modern science is now uncovering the specific bioactive compounds that make it so relevant to longevity and healthy aging,” he said. “As we await the publication of our new clinical studies on these compounds, our focus remains on translating chaga’s natural resilience into health benefits for people seeking to age well.”
KAAPA aims to unlock these bioactive compounds through its proprietary extraction process, which it claims ensures high-purity extracts with consistent potency. The company argues that this precision is critical as the global functional mushroom market faces challenges with inconsistent quality and weak analytical standards. Variability in bioactive concentration across commercial products has created uncertainty about efficacy and transparency, underscoring the need for new benchmarks.
By quantifying compounds unique to each mushroom species and standardizing batch-to-batch consistency, KAAPA aims to establish clearer efficacy markers for manufacturers and consumers alike. The measures are intended to ensure that longevity claims and health outcomes are supported by reproducible data.
Through its three divisions – KAAPA Forest, KAAPA Mushrooms and Nordic Mushrooms – the company maintains control over every stage of production. KAAPA Forest operates the world’s largest chaga cultivation network, with a focus on sustainable forest use. KAAPA Mushrooms and Nordic Mushrooms supply organic mushroom extracts derived using the company’s approach. This vertical integration, from cultivation to extraction, aims to guarantee purity and traceability of the ingredients.
The recent opening of new cultivation facilities in Paimio and Salo, significantly increased KAAPA’s production capacity and research capabilities. The newly raised capital, led by PeakBridge and Zintinus, aims to accelerate the company’s growth trajectory and advance its clinical research program on chaga and other functional species.
“Functional mushrooms represent more than a wellness trend; they’re a convergence of centuries of traditional use, growing clinical evidence, and modern extraction science that delivers measurable health benefits,” said PeakBridge partner Dr Gali Artzi.
